Sunday, September 06, 2020 11:55:09 PM
I think we stand a chance there for the very reason you note in this Post!
(I'd love to hear your opinion on what you read below):
None of the (3) Judges understood Singer was trying to get them to understand first and foremost that the Mori and Kuri studies were faulty.
The Appeals Judges kept asking Singer what Du did wrong with the Secondary Considerations and what was different than Novo.
They JUST DIDN'T UNDERSTAND his argument was 100% based on them understanding the two studies were flawed first and foremost.
He should have basically just told them to Shut Up and listen while saying: "The two flawed studies made the Secondary Considerations seem important YET they mean nothing if you review the studies to see how Du misinterpreted them!"
I listened to a very similar Patent Appeal where the Judges listened and tore apart the evidence used to incorrectly decide the case and overturned it.
Even the Novo trial summary allowed "bad" or "intentionally altered evidence" to be submitted if it could change the original verdict - see below in Bold.
I just do not think the Judges considered for a second that the Trial Judge could make a mistake with evidence.
In the En Banc Appeal, the 1st page lists the 4 or 5 complaints that ALL (9) remaining Judges MUST read and digest to determine if they will allow it to proceed.
If they allow it, Singer gets a redo with (9) Judges listening without the (15) minute time-clock running!
I honestly think Singers delivery last week was tripped up by a single loud mouth Judge who failed to listen! He already made up his mind that this Appeal was only about Secondary Considerations!
For those who disagree: Listen to Singer say over and over: Please let me make it clear - its the incorrect studies that caused the Secondary Considerations to seem important.
If the interpretation of the Evidence was done correctly, the Secondary Considerations would not be needed!
Singer totally confused them when he said: The incorrect evidence "bled over to the Secondary Considerations!"
I had NO IDEA what Singer meant until I listened two more times and kept hearing him say: The evidence was misinterpreted!
The En Banc appeal will expose the misunderstanding of the (3) Judges... I think Dyke (as an Appeal Judge in the Novo Appeal trial) told the other two: "I got this!"
Yet he completely misunderstood Singer!
I didn't!
And here is where Novo allows bad or intentionally tainted (cropped) evidence to be re-evaluated. This is 100% 'cut-and-paste' right from Novo's Summary in the final Appeal Judgement:
"The Federal Circuit found it to be a nonmaterial omission because it did not qualify as “but-for” material. The Court explained that this was not a case in which adverse results were hidden in favor of more positive data, nor did the omission undermine the opinion stated in the declaration."
In the above: Novo said the Defendants intentionally omitted evidence that would have helped Novo's case. The Appeals Judges said the "evidence" would not have changed their Obviousness decision (again in the Novo case) YET they said if evidence was intentionally changed or omitted AND effected the outcome of the original Trial, that would be a case ripe for an Overturn or Remand...
JUST LIKE OURS AND JUST LIKE SINGER TRIED TO TELL OUR APPEAL JUDGES!!!
I think the En Banc Appeal will be clear and much more revealing to the other (9) Judges!
If not, I'm moving to the Planet Mars!
Recent AMRN News
- Amarin Announces Results of Annual General Meeting of Shareholders • GlobeNewswire Inc. • 04/22/2024 12:00:25 PM
- Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024 • GlobeNewswire Inc. • 04/15/2024 12:00:00 PM
- Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • PR Newswire (Canada) • 04/08/2024 10:30:00 AM
- New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • GlobeNewswire Inc. • 04/06/2024 07:30:00 PM
- Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/04/2024 10:30:53 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/04/2024 01:00:24 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 12:06:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 12:05:56 PM
- Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/29/2024 12:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024 • GlobeNewswire Inc. • 02/15/2024 01:00:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/12/2024 01:00:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:31:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/26/2024 12:00:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/24/2024 09:31:21 PM
- Amarin Chairman & CEO Issue Letter to Shareholders • GlobeNewswire Inc. • 01/22/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 10:31:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 10:27:29 PM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM
Avant Technologies Launches Advanced AI Supercomputing Network and Expansive Data Solutions • AVAI • Apr 23, 2024 8:00 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • BLO • Apr 22, 2024 8:49 AM
Kona Gold Beverages, Inc. Prepares for First Production Run Set to Launch May 17, 2024 • KGKG • Apr 22, 2024 8:30 AM